Several synthetic lethal partners of EZH2 or mutations conferring EZH2 dependence have been identified in hematological malignancies and solid cancers, such as breast, ovarian, and non-small cell lung cancer [22–26]; reviewed by [21]. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.